CTLA4 and neoplasm: The percentage of CTLA-4-expressing CD4 + tumor-infiltrating lymphocytes decreased from 29.43 ± 4.04% in Nav1.8-Cre−/hM3Dq+ to 19.08 ± 2.80% in Nav1.8-Cre+/hM3Dq+ animals (Fig. 5A); similarly, the percentage of PD-1-expressing CD4 + tumor-infiltrating lymphocytes decreased from 15.02 ± 2.62% in Nav1.8-Cre−/hM3Dq+ to 7.85 ± 1.43% in Nav1.8-Cre+/hM3Dq+ mice (Fig. 5B, C).